Sponsors (18)
Introduced June 6, 2025 by Kelly Morrison · Last progress June 6, 2025
The bill improves patient safety for people with food allergies and celiac disease through clearer medicine labeling and may cut some emergency healthcare costs, but it imposes compliance costs on manufacturers (especially small firms) that could raise drug prices and create short-term implementation uncertainty for health systems.
People with food allergies and celiac disease will be able to identify when a medicine contains or is derived from major food allergens (including which gluten-containing grain), reducing the risk of allergic reactions and harmful exposures.
Clearer allergen/gluten labeling on medicines may reduce accidental exposures that lead to emergency care, lowering healthcare utilization and associated costs for patients and public programs.
Drug manufacturers will incur costs to change labels and comply with new requirements, which could be passed on to consumers as higher drug prices.
Smaller drug makers and compounders will face testing, verification, and relabeling burdens that could raise administrative costs or reduce product availability.
Pharmacies and hospitals could face uncertainty and operational disruption if federal implementation guidance is delayed or inconsistent during the transition to new labeling rules.
Based on analysis of 2 sections of legislative text.
Requires human drug labels to disclose ingredients that are major food allergens or gluten-containing grains and to identify each such ingredient and grain type.
Requires drug labels for products intended for humans to disclose when an ingredient is (or is derived from) a major food allergen or a gluten-containing grain, and to identify each such ingredient and, if applicable, the specific type of gluten-containing grain (wheat, barley, rye, and crossbred hybrids). The labeling duty becomes mandatory on the earlier of a date set by the HHS Secretary or two years after the law is enacted. Treats failure to include these disclosures as misbranding under federal drug labeling law, subjecting products that don't comply to existing enforcement remedies for misbranded drugs.